ADREVIEW DIN 02387034
Health Canada record
| Active ingredient(s) | IOBENGUANE 123 I 74 MBq |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | V09IX01 IOBENGUANE (123 I) |
| Original market date | 07-Mar-2013 |
| Current status date | 26-Feb-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
GE Healthcare Canada Inc. — licence 101469, currently licensed, last inspection rating C (2023-02-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing IOBENGUANE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02349493 | IODINE-123 META IODOBENZYLGUANIDINE | EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES) | Solution | IOBENGUANE 123 I 185 MBq | Cancelled Pre Market |
| 02349515 | IODINE-131 META IODOBENZYLGUANIDINE | EDMONTON RADIOPHARMACEUTICAL CENTRE (ALBERTA HEALTH SERVICES) | Solution | IOBENGUANE 131I 375 MBq | Cancelled Pre Market |